Posted innews Oncology Otorhinolaryngology
Advances in Head and Neck Cancer: How Pre-Surgical Immunotherapy is Transforming Patient Outcomes
A Phase II clinical trial demonstrates that combining tislelizumab with neoadjuvant chemotherapy significantly improves pathological response rates and organ preservation in patients with locally advanced head and neck squamous cell carcinoma.
